Acalabrutinib vs zanubrutinib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Mantle Cell Lymphoma
Shared mechanism: BTK · full Mantle Cell Lymphoma pipeline
Acalabrutinib
Marketed by AstraZeneca
NCT02213926 · Phase 2 · active, not recruiting
This was a single-arm, open-label study without randomization, blinding, or a comparator. Although the clinical response endpoint was reported in 124 participants, a comparative treatment effect could not be tested, so the evidence is limited.
Next expected readout: December 2026 · NCT04115631 (registry estimate)
Reported efficacy
Overall Response Rate (ORR) of ACP-196 (Acalabrutinib) in Subjects With Previously Treated MCL. (From the date of the first dose until 30 days after the last dose of the study drug or start of a new anti-cancer treatment, whichever came first, assessed up to approximately 4 year and 10 months. 1 cycle =28 days): Overall Response Rate (ORR) of ACP-196 (Acalabrutinib) in Subjects With Previously Treated MCL. (From the date of the first dose until 30 days after the last dose of the study drug or start of a new anti-cancer treatment, whichever came first, assessed up to approximately 4 year and 10 months. 1 cycle =28 days): ACP-196 (Acalabrutinib) — CR: 59 Participants; PR: 42 Participants; SD: 10 Participants; PD: 10 Participants; NE: 3 Participants (not_applicable)
Result source: NCT02213926
zanubrutinib · Brukinsa
Marketed by BeOne Medicines
NCT03206970 · Phase 2 · completed
All 86 participants received zanubrutinib, with no randomization, no blinding and no comparison group. The response rate cleared a fixed benchmark of 40%, but without a control group the study cannot show how much of the result is due to the drug.
Next expected readout: December 2026 · NCT06504199 (registry estimate)
Reported efficacy
Progression-free survival (PFS) determined by independent central review (Up to approximately 7 years): Primary endpoint, progression-free survival: zanubrutinib plus rituximab superior to bendamustine plus rituximab (BeOne topline, 2026-06-01). (met)
Result source: NCT04002297
Results for Mantle Cell Lymphoma
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Chronic Lymphocytic Leukemia
Shared mechanism: BTK · full Chronic Lymphocytic Leukemia pipeline
Acalabrutinib
Marketed by AstraZeneca
NCT02475681 · Phase 3 · completed
This was a randomized phase 3 trial of 535 people with an active comparator and a hard progression-free survival endpoint that was clearly met. Only outcome assessors were masked and treatment was open-label, so it is graded below the highest tier.
Next expected readout: December 2026 · NCT05971251 (registry estimate)
Reported efficacy
Progression-free Survival (PFS) Based on Independent Review Committee (IRC) Assessment (Baseline (Days -28 to -1) through 55.2 months (maximum observed duration)): Progression-free Survival (PFS) Based on Independent Review Committee (IRC) Assessment (Baseline (Days -28 to -1) through 55.2 months (maximum observed duration)): Acalabrutinib 38.4 Months (95% CI 33 to 38.6) | Ibrutinib 38.4 Months (95% CI 33 to 41.6) (met)
Result source: NCT02477696
zanubrutinib · Brukinsa
Marketed by BeOne Medicines
NCT03734016 · Phase 3 · completed
The trial was large and randomized, with 327 participants receiving zanubrutinib and 325 receiving active-comparator ibrutinib, but neither participants nor investigators were blinded. The primary clinical response endpoint was met, with statistically significant superiority for zanubrutinib by both investigator and independent review; the open-label design supports moderate rather than strong evidence.
Next expected readout: December 2026 · NCT05873712 (registry estimate)
Reported efficacy
Overall Response Rate (ORR) Assessed by the Investigator (From randomization to the final efficacy analysis cutoff date of 08 August 2022, median time on follow-up was 29.6 months (maximum of 45.2 months).); ORR Assessed by the Independent Review Committee (IRC) (From randomization to the final efficacy analysis cutoff date of 08 August 2022, median time on follow-up was 29.6 months (maximum of 45.2 months).): Overall response rate, zanubrutinib (n=327) vs ibrutinib (n=325): by independent review 86.2% vs 75.7%, response ratio 1.14 (95% CI 1.05 to 1.22), non-inferiority p<0.0001, superiority p=0.0007; by investigator 83.5% vs 74.2%, response ratio 1.12 (95% CI 1.04 to 1.22), non-inferiority p<0.0001, superiority p=0.0035 (CT.gov posted results). (met)
Result source: NCT03734016
Results for Chronic Lymphocytic Leukemia
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Acalabrutinib: registry results are on file for Chronic Lymphocytic Leukemia, but their comparison mappings are not yet available.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Acalabrutinib's landscape · zanubrutinib's landscape